Market Outlook
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size was valued at USD 1428.3 million in 2022 and is forecast to a readjusted size of USD 2826.1 million by 2029 with a CAGR of 10.2% during review period.
Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.
IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.
North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.
This report is a detailed and comprehensive analysis for global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Sales Channel. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size and forecasts, by Type and by Sales Channel, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Key Market Players
Bausch Health
Allergan
Sebela Pharmaceuticals
Astellas Pharmaceuticals
Amneal Pharms
Pharscin Pharma
Segmentation By Type
XIFAXAN
Viberzi
Lotronex
Other
Hospitals Pharmacy
Retail Pharmacy
Other
Segmentation By Region
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Market SWOT Analysis
What are the strengths of the IBS-D drugs market in 2025?
The IBS-D drugs market in 2025 is poised to benefit from ongoing advancements in drug development, including more targeted therapies. Increased awareness about IBS-D and a growing patient pool will likely drive demand. Regulatory approvals for new drugs, coupled with better patient outcomes, will strengthen market growth.
What are the weaknesses of the IBS-D drugs market in 2025?
Despite advancements, IBS-D drugs often come with high costs and limited insurance coverage, which may restrict access for some patients. Additionally, many treatments only address symptoms, not the underlying causes of the disorder, leading to chronic reliance on medication rather than a cure.
What opportunities are present in the IBS-D drugs market in 2025?
There is significant opportunity in the development of personalized and precision medicine for IBS-D, as genetic and microbiome research advances. New formulations and drug delivery systems, along with greater patient education, can enhance treatment efficacy and patient adherence. Collaborations between pharmaceutical companies and healthcare providers can also open doors to new market segments.
What are the threats to the IBS-D drugs market in 2025?
The major threat to the IBS-D drugs market is the potential for generic competition as patents expire for blockbuster treatments. Additionally, regulatory hurdles and delays in drug approvals can hinder market growth. The rising concern over side effects or long-term use of certain drugs may lead to patient hesitancy or demand for alternative therapies.
Market PESTEL Analysis
What are the political factors affecting the IBS-D drugs market in 2025?
Political factors, such as government healthcare policies and regulations regarding drug approvals, will impact the IBS-D drugs market. Changes in healthcare coverage, pricing regulations, and reimbursement policies can either facilitate or hinder market growth. Political stability and support for research funding are also crucial in fostering innovation in this field.
How do economic factors influence the IBS-D drugs market in 2025?
Economic factors like healthcare expenditure, economic growth, and disposable income levels affect the affordability of IBS-D treatments. In economically strained environments, patients may face difficulties in accessing expensive therapies, impacting demand. Additionally, economic conditions influence pharmaceutical companies' ability to invest in research and development for new drugs.
What social factors are shaping the IBS-D drugs market in 2025?
Increasing awareness about gastrointestinal disorders and a growing focus on gut health are driving demand for IBS-D treatments. Social factors such as changing dietary habits, stress levels, and an aging population are contributing to the rising prevalence of IBS-D. Social media and patient advocacy groups also play a role in educating and encouraging patients to seek treatment.
What technological factors are impacting the IBS-D drugs market in 2025?
Technological advancements in genomics, microbiome research, and personalized medicine are transforming the treatment landscape for IBS-D. New drug discovery techniques, including artificial intelligence and data analytics, allow for faster development of more effective therapies. Innovations in drug delivery methods and digital health tools for patient monitoring are also enhancing treatment options.
What environmental factors should be considered in the IBS-D drugs market in 2025?
Environmental factors such as climate change, pollution, and environmental stressors can exacerbate gastrointestinal issues, potentially increasing the prevalence of IBS-D. Additionally, the pharmaceutical industry must consider sustainable practices in drug production, packaging, and waste disposal to meet growing environmental regulations.
What legal factors are relevant to the IBS-D drugs market in 2025?
Legal factors such as intellectual property laws, patent expirations, and international regulations governing drug safety and efficacy are crucial in shaping the IBS-D drugs market. Legal challenges related to drug approvals, clinical trials, and product liability must also be considered by pharmaceutical companies as they bring new treatments to market.
Market SIPOC Analysis
Who are the suppliers in the IBS-D drugs market in 2025?
Suppliers in the IBS-D drugs market include pharmaceutical companies, biotechnology firms, raw material suppliers, and contract manufacturing organizations. These suppliers provide the necessary active pharmaceutical ingredients (APIs), formulations, packaging materials, and other components for drug production.
What are the inputs required for the IBS-D drugs market in 2025?
Inputs include the development of pharmaceutical compounds, clinical trial data, regulatory approvals, research on gut health and microbiomes, as well as market research data on IBS-D prevalence and patient needs. Investment in production facilities and the raw materials for drug formulations are also key inputs.
What are the processes involved in the IBS-D drugs market in 2025?
The processes include drug discovery and development, clinical trials, regulatory approval, manufacturing, and distribution. Additionally, marketing and sales strategies to promote IBS-D treatments to healthcare professionals and patients, along with post-market surveillance and pharmacovigilance, are essential to ensure drug safety and efficacy.
What are the outputs of the IBS-D drugs market in 2025?
Outputs in the IBS-D drugs market include approved pharmaceutical products, such as oral medications, oral therapies, and new drug formulations tailored for IBS-D patients. The output also includes market awareness, improved patient care, and increased patient adherence to prescribed treatments, leading to better health outcomes.
Who are the customers in the IBS-D drugs market in 2025?
Customers in the IBS-D drugs market include healthcare providers (such as gastroenterologists and general practitioners), hospitals, pharmacies, and patients suffering from IBS-D. Pharmaceutical distributors and insurance companies also play a role in shaping the customer base by affecting drug availability and affordability.
Market Porter's Five Forces
What is the threat of new entrants in the IBS-D drugs market in 2025?
The threat of new entrants in the IBS-D drugs market is moderate. While the market is growing, the high barriers to entry, including the substantial investment required for research and development, regulatory approvals, and manufacturing capabilities, can deter new competitors. Established companies with existing market share have an advantage in terms of brand recognition and distribution channels.
What is the bargaining power of suppliers in the IBS-D drugs market in 2025?
The bargaining power of suppliers is relatively moderate. While there are a few key suppliers for active pharmaceutical ingredients (APIs) and drug manufacturing, the increasing number of generic drug manufacturers and technological advancements in drug production offer companies some leverage in negotiations. However, any disruption in the supply chain could impact production, especially for niche treatments.
What is the bargaining power of buyers in the IBS-D drugs market in 2025?
The bargaining power of buyers, including patients and healthcare providers, is relatively high. Patients are becoming more informed about treatment options and may demand more affordable or effective drugs. Healthcare providers, particularly larger institutions and insurance companies, also influence pricing and access to IBS-D treatments, often pushing for cost-effective solutions.
What is the threat of substitute products in the IBS-D drugs market in 2025?
The threat of substitutes is moderate. While there are no direct substitutes to prescription medications for IBS-D, alternative treatments such as dietary changes, probiotics, and over-the-counter products can provide relief. These alternatives may be preferred by patients seeking less costly or non-pharmaceutical options, impacting demand for prescribed drugs.
What is the intensity of competitive rivalry in the IBS-D drugs market in 2025?
The intensity of competitive rivalry in the IBS-D drugs market is high. The market is characterized by a few major pharmaceutical companies that dominate the landscape, but there is significant competition for market share as new treatments are introduced. Companies are vying for approval of novel drugs, and with patent expirations, generic competitors will also increase rivalry in the market.
Market Upstream Analysis
What are the key upstream factors affecting the IBS-D drugs market in 2025?
Key upstream factors include the availability of raw materials for drug production, research and development capabilities, and regulatory requirements for drug approval. Additionally, the advancement of scientific knowledge in areas such as gut microbiomes and personalized medicine will influence drug development and the pipeline of new therapies.
How do pharmaceutical suppliers impact the IBS-D drugs market in 2025?
Pharmaceutical suppliers play a crucial role in providing the necessary active pharmaceutical ingredients (APIs) and excipients required to manufacture IBS-D drugs. The stability and cost of these supplies can significantly impact production timelines, pricing, and overall market supply. Suppliers of specialized components like biologicals and innovative drug delivery systems are also key to developing next-generation therapies.
What role does research and development (R&D) play in the IBS-D drugs market in 2025?
R&D is at the core of innovation in the IBS-D drugs market. Advances in molecular biology, genomics, and microbiome research directly affect the development of new drugs with better efficacy and fewer side effects. The R&D pipeline will determine the availability of novel treatments, making it a critical upstream factor in shaping the market in 2025.
How do regulatory factors influence the IBS-D drugs market in 2025?
Regulatory agencies, such as the FDA, play a significant role in shaping the upstream landscape by establishing the standards and approval processes for new drugs. Stricter regulations and longer approval timelines may delay market entry, while faster approval processes can enhance market growth. Regulatory decisions regarding safety, efficacy, and labeling can also impact the market's competitiveness and product availability.
What impact does intellectual property (IP) have on the IBS-D drugs market in 2025?
Intellectual property (IP) plays a pivotal role in protecting innovations and maintaining competitive advantages in the IBS-D drugs market. Patents for new drugs or drug delivery systems help companies secure market exclusivity, which impacts pricing and profits. However, the expiration of patents opens up opportunities for generics, which can affect market dynamics and pricing strategies.
Market Midstream Analysis
What are the key midstream factors impacting the IBS-D drugs market in 2025?
Key midstream factors include the manufacturing process, quality control, and distribution networks for IBS-D drugs. Effective scaling of production, efficient supply chain management, and ensuring regulatory compliance during manufacturing are essential to meeting market demand. Distribution networks, including partnerships with wholesalers, retailers, and pharmacies, also influence drug accessibility.
How does manufacturing capacity affect the IBS-D drugs market in 2025?
Manufacturing capacity is crucial to ensuring a steady supply of IBS-D drugs to the market. Companies with robust manufacturing facilities that can handle large-scale production and meet regulatory standards will have a competitive edge. However, limitations in capacity can lead to supply shortages, delaying drug availability and impacting market share.
What role do partnerships play in the midstream of the IBS-D drugs market?
Partnerships, especially with contract manufacturers, logistics providers, and distributors, are essential for expanding the reach of IBS-D drugs. These collaborations enable companies to scale their production, improve distribution efficiency, and expand into new markets, driving growth. They also help optimize costs and streamline the overall supply chain process.
How do logistics and distribution networks impact the IBS-D drugs market?
Effective logistics and distribution networks ensure that IBS-D drugs reach healthcare providers and patients in a timely and cost-effective manner. A strong distribution system reduces lead times and enhances drug availability, especially in global markets. Distribution partnerships with pharmaceutical wholesalers, pharmacies, and hospitals are critical for widespread market penetration.
What impact does regulatory compliance have on the midstream of the IBS-D drugs market in 2025?
Regulatory compliance during the midstream phase ensures that the manufacturing and distribution processes adhere to local and international standards. This includes meeting Good Manufacturing Practices (GMP), ensuring product safety, and maintaining quality control throughout the production cycle. Non-compliance can result in product recalls, delays, and loss of market trust, which can significantly affect revenue and market position.
Market Downstream Analysis
What are the key downstream factors influencing the IBS-D drugs market in 2025?
Key downstream factors include the marketing and sales strategies, patient access to medications, and healthcare provider adoption. The way drugs are promoted, prescribed, and reimbursed impacts their success in the market. Patient education, awareness campaigns, and effective sales force strategies are crucial in ensuring widespread adoption of IBS-D drugs.
How do healthcare providers affect the IBS-D drugs market in 2025?
Healthcare providers, particularly gastroenterologists, play a significant role in the downstream market by prescribing IBS-D treatments. Their awareness of new drugs, their understanding of treatment efficacy, and their relationship with pharmaceutical companies influence drug adoption. Effective communication between pharmaceutical companies and healthcare providers can enhance treatment outcomes and encourage proper patient care.
What is the role of patient access and affordability in the IBS-D drugs market?
Patient access and affordability are critical downstream factors. With the high cost of some IBS-D medications, the ability to access these treatments can be limited, especially for uninsured or underinsured patients. Insurance coverage, patient assistance programs, and pricing strategies all play a role in determining whether patients can obtain the necessary medications, which directly impacts market success.
How do marketing and promotional strategies influence the IBS-D drugs market?
Marketing and promotional strategies are vital for creating awareness and driving demand for IBS-D drugs. Targeted marketing campaigns that educate both healthcare professionals and patients about new treatments can enhance market penetration. Strong branding, professional endorsements, and digital marketing efforts can also contribute to higher visibility and increased prescriptions.
What impact does regulatory approval and reimbursement have on the IBS-D drugs market?
Regulatory approval and reimbursement policies are essential downstream factors in determining drug accessibility and profitability. Drugs that receive quick approval and are included in insurance formularies are more likely to be prescribed and used by patients. Conversely, delayed approval or lack of reimbursement can limit a drug’s market share, hindering its success and patient accessibility.
Chapter 1, to describe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, with price, sales, revenue and global market share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs from 2018 to 2023.
Chapter 3, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and sales channel, with sales market share and growth rate by type, sales channel, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market forecast, by regions, type and sales channel, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.
Chapter 14 and 15, to describe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 XIFAXAN
1.3.3 Viberzi
1.3.4 Lotronex
1.3.5 Other
1.4 Market Analysis by Sales Channel
1.4.1 Overview: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Sales Channel: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals Pharmacy
1.4.3 Retail Pharmacy
1.4.4 Other
1.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size & Forecast
1.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity (2018-2029)
1.5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Bausch Health
2.1.1 Bausch Health Details
2.1.2 Bausch Health Major Business
2.1.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
2.1.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bausch Health Recent Developments/Updates
2.2 Allergan
2.2.1 Allergan Details
2.2.2 Allergan Major Business
2.2.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
2.2.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Allergan Recent Developments/Updates
2.3 Sebela Pharmaceuticals
2.3.1 Sebela Pharmaceuticals Details
2.3.2 Sebela Pharmaceuticals Major Business
2.3.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
2.3.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Sebela Pharmaceuticals Recent Developments/Updates
2.4 Astellas Pharmaceuticals
2.4.1 Astellas Pharmaceuticals Details
2.4.2 Astellas Pharmaceuticals Major Business
2.4.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
2.4.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Astellas Pharmaceuticals Recent Developments/Updates
2.5 Amneal Pharms
2.5.1 Amneal Pharms Details
2.5.2 Amneal Pharms Major Business
2.5.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
2.5.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Amneal Pharms Recent Developments/Updates
2.6 Pharscin Pharma
2.6.1 Pharscin Pharma Details
2.6.2 Pharscin Pharma Major Business
2.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
2.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Pharscin Pharma Recent Developments/Updates
3 Competitive Environment: Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Manufacturer
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer Market Share in 2022
3.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Overall Company Footprint Analysis
3.5.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Region Footprint
3.5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Company Product Type Footprint
3.5.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region
4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Region (2018-2029)
4.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value (2018-2029)
4.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value (2018-2029)
4.5 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2018-2029)
5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Type (2018-2029)
5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Type (2018-2029)
6 Market Segment by Sales Channel
6.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2018-2029)
6.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Sales Channel (2018-2029)
6.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Sales Channel (2018-2029)
7 North America
7.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2018-2029)
7.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2018-2029)
7.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
7.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2018-2029)
8.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
8.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2018-2029)
9.3 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region
9.3.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2018-2029)
10.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2018-2029)
10.3 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
10.3.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2018-2029)
11.3 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
11.3.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers
12.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
12.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
13.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Process
13.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Typical Distributors
14.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Sales Channel, (USD Million), 2018 & 2022 & 2029
Table 3. Bausch Health Basic Information, Manufacturing Base and Competitors
Table 4. Bausch Health Major Business
Table 5. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 6. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Bausch Health Recent Developments/Updates
Table 8. Allergan Basic Information, Manufacturing Base and Competitors
Table 9. Allergan Major Business
Table 10. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 11. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Allergan Recent Developments/Updates
Table 13. Sebela Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 14. Sebela Pharmaceuticals Major Business
Table 15. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 16. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Sebela Pharmaceuticals Recent Developments/Updates
Table 18. Astellas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Astellas Pharmaceuticals Major Business
Table 20. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 21. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Astellas Pharmaceuticals Recent Developments/Updates
Table 23. Amneal Pharms Basic Information, Manufacturing Base and Competitors
Table 24. Amneal Pharms Major Business
Table 25. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 26. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Amneal Pharms Recent Developments/Updates
Table 28. Pharscin Pharma Basic Information, Manufacturing Base and Competitors
Table 29. Pharscin Pharma Major Business
Table 30. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 31. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Pharscin Pharma Recent Developments/Updates
Table 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 35. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Manufacturer (2018-2023) & (USD/Unit)
Table 36. Market Position of Manufacturers in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 37. Head Office and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Site of Key Manufacturer
Table 38. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Company Product Type Footprint
Table 39. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Company Product Application Footprint
Table 40. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs New Market Entrants and Barriers to Market Entry
Table 41. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 42. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 43. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 44. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 45. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Region (2018-2023) & (USD/Unit)
Table 47. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Region (2024-2029) & (USD/Unit)
Table 48. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 49. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 50. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 51. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 52. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Type (2018-2023) & (USD/Unit)
Table 53. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Type (2024-2029) & (USD/Unit)
Table 54. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2018-2023) & (K Units)
Table 55. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2024-2029) & (K Units)
Table 56. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Sales Channel (2018-2023) & (USD Million)
Table 57. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Sales Channel (2024-2029) & (USD Million)
Table 58. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Sales Channel (2018-2023) & (USD/Unit)
Table 59. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Sales Channel (2024-2029) & (USD/Unit)
Table 60. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 61. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 62. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2018-2023) & (K Units)
Table 63. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2024-2029) & (K Units)
Table 64. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 65. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 66. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 67. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 68. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2018-2023) & (K Units)
Table 71. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2024-2029) & (K Units)
Table 72. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 73. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 74. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 75. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 76. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 77. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 78. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2018-2023) & (K Units)
Table 79. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2024-2029) & (K Units)
Table 80. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 81. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 82. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 83. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 84. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 85. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 86. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2018-2023) & (K Units)
Table 87. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2024-2029) & (K Units)
Table 88. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 89. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 90. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 91. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 92. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 93. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 94. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2018-2023) & (K Units)
Table 95. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Sales Channel (2024-2029) & (K Units)
Table 96. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 97. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 98. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 99. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 100. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Raw Material
Table 101. Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Raw Materials
Table 102. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Typical Distributors
Table 103. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Typical Customers
List of Figures
Figure 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Picture
Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value Market Share by Type in 2022
Figure 4. XIFAXAN Examples
Figure 5. Viberzi Examples
Figure 6. Lotronex Examples
Figure 7. Other Examples
Figure 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Sales Channel, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value Market Share by Sales Channel in 2022
Figure 10. Hospitals Pharmacy Examples
Figure 11. Retail Pharmacy Examples
Figure 12. Other Examples
Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price (2018-2029) & (USD/Unit)
Figure 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Type (2018-2029) & (USD/Unit)
Figure 32. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Sales Channel (2018-2029)
Figure 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value Market Share by Sales Channel (2018-2029)
Figure 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Sales Channel (2018-2029) & (USD/Unit)
Figure 35. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Sales Channel (2018-2029)
Figure 37. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Sales Channel (2018-2029)
Figure 44. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Sales Channel (2018-2029)
Figure 53. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value Market Share by Region (2018-2029)
Figure 55. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Sales Channel (2018-2029)
Figure 63. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Sales Channel (2018-2029)
Figure 69. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers
Figure 76. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
Figure 77. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in 2022
Figure 80. Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 81. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
